Summary: Daxor expanded its ezBVA Lab service to two major health systems, offering blood volume analysis to improve fluid management and reduce hospitalizations.
Takeaways:
- Innovative Outpatient Solutions: Daxor’s ezBVA Lab delivers real-time insights into fluid imbalances and cardiovascular risks, empowering clinicians to personalize treatment and prevent costly hospitalizations.
- Broad Adoption: The service is now implemented for outpatient nephrology care at a leading Arizona medical center and heart failure management across a multi-state regional health network.
- Commercial Success: Daxor’s clinical education efforts and commercialization strategy have driven record revenue growth and increasing adoption across healthcare systems.
Daxor Corporation, a provider in blood volume measurement technology, announced the expansion of its ezBVA Lab service to two new health systems.
Daxor’s ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement coverage across hospitals and ambulatory care settings.
“Our BVA platform is a critical diagnostic tool that redefines outpatient care by providing real-time insights into a patient’s volume status. By enabling early detection of fluid imbalances and cardiovascular risks, BVA empowers clinicians to intervene proactively, potentially preventing costly hospitalizations, reducing emergency interventions, and personalizing patient treatment strategies,” says John Jefferies, Daxor’s chief medical officer.
Details of the Announcement:
- A major Arizona-based multi-campus medical center has adopted the company’s BVA technology for outpatient nephrology care with further departments to follow in 2025.
- A regional health network serving communities across Southwest Iowa, Nebraska, Minnesota, and North Dakota has agreed to implement BVA for heart failure outpatient management.
“The continued sales growth that the company is experiencing has positioned us for our best quarter ever in terms of revenue and year-over-year growth reflecting the focus of our commercialization team and the increasing customer engagement driven by our clinical education team,” says Michael Feldschuh, Daxor’s CEO and president.
